Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Supernus Pharmaceuticals (SUPN) Current Leases: 2019-2020

Supernus Pharmaceuticals' Current Leases was N/A to $3.7 million in Q3 2020 from the same period last year, while for Sep 2020 it was $3.7 million, marking a year-over-year change of. This contributed to the annual value of $2.8 million for FY2019, which is N/A change from last year.
Supernus Pharmaceuticals' Current Leases amounted to $3.7 million in Q3 2020, which was down 10.95% from $4.2 million recorded in Q2 2020.
In the past 5 years, Supernus Pharmaceuticals' Current Leases ranged from a high of $4.2 million in Q2 2020 and a low of $2.8 million during Q4 2019.
Its 2-year average for Current Leases is $3.6 million, with a median of $3.7 million in 2020.